CN107927797A - 一种供肌肉衰减综合征人群食用含短肽的全营养食品配方 - Google Patents
一种供肌肉衰减综合征人群食用含短肽的全营养食品配方 Download PDFInfo
- Publication number
- CN107927797A CN107927797A CN201711309348.9A CN201711309348A CN107927797A CN 107927797 A CN107927797 A CN 107927797A CN 201711309348 A CN201711309348 A CN 201711309348A CN 107927797 A CN107927797 A CN 107927797A
- Authority
- CN
- China
- Prior art keywords
- food
- vitamin
- small peptide
- muscle
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 73
- 210000003205 muscle Anatomy 0.000 title claims abstract description 63
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 34
- 235000020795 whole food diet Nutrition 0.000 title claims abstract description 11
- 239000000284 extract Substances 0.000 claims abstract description 53
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims abstract description 46
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 24
- 239000011707 mineral Substances 0.000 claims abstract description 24
- 239000006046 creatine Substances 0.000 claims abstract description 23
- 229960003624 creatine Drugs 0.000 claims abstract description 23
- 229940088594 vitamin Drugs 0.000 claims abstract description 17
- 235000013343 vitamin Nutrition 0.000 claims abstract description 17
- 239000011782 vitamin Substances 0.000 claims abstract description 17
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 16
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 15
- 229930003231 vitamin Natural products 0.000 claims abstract description 15
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 15
- 244000144725 Amygdalus communis Species 0.000 claims abstract description 13
- 235000011437 Amygdalus communis Nutrition 0.000 claims abstract description 13
- 240000008669 Hedera helix Species 0.000 claims abstract description 13
- 235000020224 almond Nutrition 0.000 claims abstract description 13
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 13
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 13
- 210000000582 semen Anatomy 0.000 claims abstract description 13
- 241000218231 Moraceae Species 0.000 claims abstract description 12
- 241000411851 herbal medicine Species 0.000 claims abstract description 12
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000011575 calcium Substances 0.000 claims abstract description 10
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 3
- 235000021056 liquid food Nutrition 0.000 claims abstract 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 28
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 16
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 14
- 229960004488 linolenic acid Drugs 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 10
- 108010038807 Oligopeptides Proteins 0.000 claims description 10
- 102000015636 Oligopeptides Human genes 0.000 claims description 9
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- 108010073771 Soybean Proteins Proteins 0.000 claims description 8
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 8
- 229910052742 iron Inorganic materials 0.000 claims description 8
- 102000007544 Whey Proteins Human genes 0.000 claims description 7
- 108010046377 Whey Proteins Proteins 0.000 claims description 7
- 229940001941 soy protein Drugs 0.000 claims description 7
- 235000021119 whey protein Nutrition 0.000 claims description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 6
- 239000011701 zinc Substances 0.000 claims description 6
- 229910052725 zinc Inorganic materials 0.000 claims description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 5
- 241000209140 Triticum Species 0.000 claims description 5
- 235000021307 Triticum Nutrition 0.000 claims description 5
- 229930003268 Vitamin C Natural products 0.000 claims description 5
- 229960003512 nicotinic acid Drugs 0.000 claims description 5
- 235000001968 nicotinic acid Nutrition 0.000 claims description 5
- 239000011664 nicotinic acid Substances 0.000 claims description 5
- 235000019154 vitamin C Nutrition 0.000 claims description 5
- 239000011718 vitamin C Substances 0.000 claims description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 4
- 241000251468 Actinopterygii Species 0.000 claims description 4
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 4
- 241000237502 Ostreidae Species 0.000 claims description 4
- 108010084695 Pea Proteins Proteins 0.000 claims description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 4
- 229930003316 Vitamin D Natural products 0.000 claims description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 4
- 229930003427 Vitamin E Natural products 0.000 claims description 4
- 240000008042 Zea mays Species 0.000 claims description 4
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 4
- 229960000304 folic acid Drugs 0.000 claims description 4
- 235000019152 folic acid Nutrition 0.000 claims description 4
- 239000011724 folic acid Substances 0.000 claims description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 4
- 235000020636 oyster Nutrition 0.000 claims description 4
- 235000019702 pea protein Nutrition 0.000 claims description 4
- 235000019155 vitamin A Nutrition 0.000 claims description 4
- 239000011719 vitamin A Substances 0.000 claims description 4
- 239000011691 vitamin B1 Substances 0.000 claims description 4
- 239000011715 vitamin B12 Substances 0.000 claims description 4
- 235000019166 vitamin D Nutrition 0.000 claims description 4
- 239000011710 vitamin D Substances 0.000 claims description 4
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 4
- 235000019165 vitamin E Nutrition 0.000 claims description 4
- 239000011709 vitamin E Substances 0.000 claims description 4
- 229940046009 vitamin E Drugs 0.000 claims description 4
- 229940045997 vitamin a Drugs 0.000 claims description 4
- 229940046008 vitamin d Drugs 0.000 claims description 4
- 241000251511 Holothuroidea Species 0.000 claims description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 3
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 claims description 3
- 235000009973 maize Nutrition 0.000 claims description 3
- 239000011574 phosphorus Substances 0.000 claims description 3
- 229910052698 phosphorus Inorganic materials 0.000 claims description 3
- 239000011716 vitamin B2 Substances 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 2
- 230000000975 bioactive effect Effects 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 229910052711 selenium Inorganic materials 0.000 claims description 2
- 239000011669 selenium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims 1
- 238000000227 grinding Methods 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 58
- 239000003814 drug Substances 0.000 abstract description 23
- 102000004169 proteins and genes Human genes 0.000 abstract description 23
- 108090000623 proteins and genes Proteins 0.000 abstract description 23
- 239000000203 mixture Substances 0.000 abstract description 16
- 230000015572 biosynthetic process Effects 0.000 abstract description 15
- 230000003387 muscular Effects 0.000 abstract description 14
- 238000003786 synthesis reaction Methods 0.000 abstract description 14
- 238000009472 formulation Methods 0.000 abstract description 11
- 210000004185 liver Anatomy 0.000 abstract description 9
- 210000003734 kidney Anatomy 0.000 abstract description 6
- 102000008934 Muscle Proteins Human genes 0.000 abstract description 5
- 108010074084 Muscle Proteins Proteins 0.000 abstract description 5
- 206010003694 Atrophy Diseases 0.000 abstract 1
- 230000037444 atrophy Effects 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical class CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 24
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 23
- 235000018102 proteins Nutrition 0.000 description 22
- 230000006870 function Effects 0.000 description 21
- 235000010755 mineral Nutrition 0.000 description 20
- 235000016709 nutrition Nutrition 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- 239000000843 powder Substances 0.000 description 14
- 235000015097 nutrients Nutrition 0.000 description 13
- 239000012141 concentrate Substances 0.000 description 12
- 239000002253 acid Substances 0.000 description 10
- 235000013399 edible fruits Nutrition 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 230000012010 growth Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000036541 health Effects 0.000 description 9
- 230000035764 nutrition Effects 0.000 description 9
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- 230000036039 immunity Effects 0.000 description 8
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 8
- 235000020778 linoleic acid Nutrition 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 7
- 230000029087 digestion Effects 0.000 description 7
- 206010016256 fatigue Diseases 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 125000001931 aliphatic group Chemical group 0.000 description 6
- 235000013312 flour Nutrition 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 244000060011 Cocos nucifera Species 0.000 description 4
- 235000013162 Cocos nucifera Nutrition 0.000 description 4
- WHGYBXFWUBPSRW-UHFFFAOYSA-N Cycloheptaamylose Natural products O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO WHGYBXFWUBPSRW-UHFFFAOYSA-N 0.000 description 4
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 239000005913 Maltodextrin Substances 0.000 description 4
- 229920002774 Maltodextrin Polymers 0.000 description 4
- 240000000249 Morus alba Species 0.000 description 4
- 239000004383 Steviol glycoside Substances 0.000 description 4
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 229940035034 maltodextrin Drugs 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- 229930182488 steviol glycoside Natural products 0.000 description 4
- 235000019411 steviol glycoside Nutrition 0.000 description 4
- 150000008144 steviol glycosides Chemical class 0.000 description 4
- 235000019202 steviosides Nutrition 0.000 description 4
- 208000010392 Bone Fractures Diseases 0.000 description 3
- 102000015781 Dietary Proteins Human genes 0.000 description 3
- 108010010256 Dietary Proteins Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010017076 Fracture Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 235000021245 dietary protein Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000019688 fish Nutrition 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 210000004347 intestinal mucosa Anatomy 0.000 description 3
- 150000002614 leucines Chemical class 0.000 description 3
- -1 methionine amino acid Chemical class 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 239000011726 vitamin B6 Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- MKMCJLMBVKHUMS-UHFFFAOYSA-N Coixol Chemical compound COC1=CC=C2NC(=O)OC2=C1 MKMCJLMBVKHUMS-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 235000017443 Hedysarum boreale Nutrition 0.000 description 2
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010062575 Muscle contracture Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229930194270 alpha-Vitamin Natural products 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 208000006111 contracture Diseases 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000004626 essential fatty acids Nutrition 0.000 description 2
- 239000002360 explosive Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 2
- 239000001685 glycyrrhizic acid Substances 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 201000005630 leukorrhea Diseases 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 229940118019 malondialdehyde Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- GSSMIHQEWAQUPM-AOLPDKKJSA-N ovalbumin peptide Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CN=CN1 GSSMIHQEWAQUPM-AOLPDKKJSA-N 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 230000001228 trophic effect Effects 0.000 description 2
- 206010046901 vaginal discharge Diseases 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- KSDSYIXRWHRPMN-UHFFFAOYSA-N 4'-O-beta-D-Galactopyranoside-6''-p-Coumaroylprunin-4',5,7-Trihydroxyflavanone Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC(O)=C3C(=O)C2)C=C1 KSDSYIXRWHRPMN-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 229940122816 Amylase inhibitor Drugs 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 102000040350 B family Human genes 0.000 description 1
- 108091072128 B family Proteins 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 235000004936 Bromus mango Nutrition 0.000 description 1
- 102100034279 Calcium-binding mitochondrial carrier protein Aralar2 Human genes 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000276435 Gadus Species 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 101000693916 Gallus gallus Albumin Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 229930194248 Licoflavone Natural products 0.000 description 1
- MEHHCBRCXIDGKZ-UHFFFAOYSA-N Licoflavone C Natural products CC(C)=CCC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 MEHHCBRCXIDGKZ-UHFFFAOYSA-N 0.000 description 1
- DEMKZLAVQYISIA-ONJCETCRSA-N Liquiritin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc([C@@H]2Oc3c(C(=O)C2)ccc(O)c3)cc1 DEMKZLAVQYISIA-ONJCETCRSA-N 0.000 description 1
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000007228 Mangifera indica Species 0.000 description 1
- 235000014826 Mangifera indica Nutrition 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- IKGXIBQEEMLURG-UHFFFAOYSA-N Rutin Chemical compound OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 235000009184 Spondias indica Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 240000008866 Ziziphus nummularia Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000003392 amylase inhibitor Substances 0.000 description 1
- 230000006538 anaerobic glycolysis Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000003130 cardiopathic effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 108010084210 citrin Proteins 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- DEMKZLAVQYISIA-ZRWXNEIDSA-N liquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([C@H]2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-ZRWXNEIDSA-N 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 238000005424 photoluminescence Methods 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明提供了一种供肌肉衰减综合征人群食用含短肽的全营养食品配方,该特殊医学用途配方食品以食源性短肽为主要原料,添加薏苡仁、酸枣仁、桑葚、杏仁、白扁豆、甘草等传统的药食两用中草药浓缩提取物,再辅以β‑羟基‑β‑甲基丁酸钙、肌酸、低聚糖、多种维生素和矿物质,组成复合配方。采用该配方可以制成粉状或颗粒状或液体状食品。按照本发明配方制备的食品,不仅可以及时为肌肉衰减综合征人群提供所需优质蛋白质、维生素及矿物质,不增加肝肾负担;同时能够显著提高其肌力量与LBM,增加蛋白合成,防止肌肉流失与萎缩,抑制肌肉蛋白降解,保护肌肉组织。本发明提出的含短肽的特殊医学用途配方食品适合肌肉衰减综合征人群食用。
Description
技术领域
本发明涉及一种特殊医学用途配方食品的配方,尤其是涉及一种以短肽补充蛋白质,补充维生素和矿物质,并利用药食两用中草药中的功能因子调节机体功能,同时利用肌酸和新资源食品β-羟基-β-甲基丁酸钙(HMB)可显著改善肌肉量和肌力的特点,适合肌肉衰减综合征人群食用的特殊医学用途配方食品的特定全营养配方。
背景技术
肌肉是人体重要的组成部分,肌肉在全身蛋白代谢中起核心作用。正常人的肌肉占体重的35%-45%。流行病学研究显示,人体的肌肉量随年龄的增长而不断地衰减。50岁以后,肌肉量平均每年减少1%-2%,60岁以后慢性肌肉丢失约30%,80岁后约丢失50%,当肌肉减少30%将影响肌肉的正常功能,导致走路不稳、行走困难,甚至跌倒、骨折。一旦骨折长期卧床,又会加重肌肉流失、骨量下降,严重影响生活质量。肌肉衰减综合征是指老年人因活动减少、卧床、营养不良慢性疾病引起的骨骼肌量和骨骼肌力量及功能下降的一种病症。研究发现,肌肉衰减综合征是骨质疏松、骨关节炎等疾病发展的重要因素之一,肌肉衰减综合征已严重影响中老年人正常生活,会导致老年人丧失自理能力、伤残、住院;并且还增加罹患糖尿病、关节炎、骨质疏松症、心脏病等疾病的危险,最终使病死率增加。
有效的营养补充是改善肌肉衰减综合征人群营养状况的主要手段之一。蛋白质摄入的质和量是影响肌肉衰减综合征的一个重要因素。膳食蛋白质供给量(RDA)0.8g.kg-1/d不能维持老年人的骨骼肌的健康,老年人膳食蛋白质摄入量增至1.0-1.3g.kg-1/d有助于维持氮平衡,并有可能降低因能量摄入减少所引起的蛋白质合成能力的下降。膳食蛋白质必需氨基酸含量(特别是亮氨酸)及其消化率和利用率是两个关键因素。亮氨酸可通过激活哺乳动物雷帕霉素帕蛋白和转译起始因子途径促进蛋白质的合成,促蛋白质合成能力比其它氨基酸高10倍。β-羟基-β-甲基丁酸钙(HMB)是亮氨酸的代谢产物,对肌肉的质量和力量上有明显的改善作用。肌酸(creatine)是一种自然存在于脊椎动物体内的一种含氮的有机酸,能够辅助为肌肉和神经细胞提供能量。
现在国内外均提倡采用特殊营养食品,对肌肉衰减综合征等的特定人群进行营养补充和改善。这在美国、欧盟等发达国家已有开发和应用。美国食品药品监督管理局(FDA)将特殊营养食品定义为“医疗食品(medical foods)”。欧盟特殊膳食的委员会颁布指令(COMMISSION DIRECTIVE 1999/21/EC of 25 March 1999)将特殊营养食品定义为“以医疗为目的的特殊膳食”。我国将特殊营养食品命名为“特殊医学用途配方食品”,并在我国的《食品安全国家标准 特殊医学用途配方食品通则》(GB 29922)及《食品安全国家标准预包装特殊膳食用食品标签》(GB 13432)中规定,特殊医学用途配方食品是为满足进食受限、消化吸收障碍、代谢紊乱或特定疾病状态人群对营养素或膳食的特殊需求,专门加工配制而成的配方食品。因此,根据肌肉衰减综合征人群的代谢特点和营养需求,选择适宜的食物原料和营养素,制备供肌肉衰减综合征人群食用的特定全营养配方食品,用于改善肌肉衰减综合征人群的营养状况及代谢状况,增加其蛋白合成,防止肌肉流失,从而进一步防治慢病的发展,也符合国家的政策导向和全民大健康标准要求。
氮源的选择是肌肉衰减综合征人群营养支持的关键。科学研究证实,利用生物酶解方法从蛋白质中提取的短肽是一类小分子蛋白质,它不需消化即可吸收,并且在吸收过程中,载体不易饱和,耗能少,速度快,优于氨基酸和完整的蛋白质,是机体的优质氮源。
药食同源性食物在我国历史悠久,应用广泛。这类食物不仅可作为食物,为人体提供营养功能,而且还具有很高的药用价值,提供一定的治疗作用。国家卫生部于2002年颁布了“既是食品又是药品的物品名单(卫法监发[2002]51号)”,为传统中草药在食品中的应用提供的依据。
肌酸是由精氨酸、甘氨酸及甲硫氨酸三种氨基酸所合成的物质。可以由人体自行合成,也可以由食物中摄取。肌酸,是人体内自然产生的一种氨基酸衍生物,它可以快速增加肌肉力量,加速疲劳恢复,提高爆发力。肌酸在人体内储存越多,力量及运动能力也越强。及时补充肌酸可以有效的提高肌力、速度和耐力,防止疲劳。
新资源食品的β-羟基-β-甲基丁酸钙(HMB)是亮氨酸的代谢产物,对肌肉的质量和力量上有明显的改善作用,可有效促进肌肉再生,提高肌力量与LBM;可增加蛋白合成,防止肌肉流失;同时抑制肌肉蛋白降解,保护肌肉组织。
在专利文献中,也有一些专门针对肌肉衰减综合征人群的药品或保健食品,但根据专利文献和非专利文献,还未发现根据肌肉衰减综合征人群代谢特点和营养需求、以食源性短肽和传统药食同源食物为主要原料,特别添加肌酸及新资源食品β-羟基-β-甲基丁酸钙(HMB)而制备的专门供肌肉衰减综合征人群食用的短肽特殊医学用途配方食品。
发明内容
本发明的目的是根据肌肉衰减综合征人群的代谢特点和营养需求,结合中肌肉衰减综合征人群营养支持的原则,提供了一种包含食源性生物活性短肽、传统的药食两用中草药、肌酸、新资源食品β-羟基-β-甲基丁酸钙(HMB)、低聚糖、亚油酸、α-亚麻酸、维生素和矿物质的特殊医学配方食品的特定全营养配方。该短肽特殊医学用途配方食品不仅可以及时为肌肉衰减综合征人群提供所需的优质蛋白质、维生素及矿物质,不增加肝肾负担;同时能够显著提高其肌力量与LBM,增加蛋白合成,防止肌肉流失,抑制肌肉蛋白降解,保护肌肉组织;从而达到加快卧床康复,防止肌肉萎缩,防治慢病发展的目的。本发明提出的短肽特殊医学用途配方食品适合肌肉衰减综合征人群食用。
本发明提出的短肽特殊医学用途配方食品是以短肽为主要原料,再添加传统的药食两用中草药浓缩提取物、肌酸、新资源食品β-羟基-β-甲基丁酸钙(HMB)、低聚糖、亚油酸、α-亚麻酸、维生素、矿物质,组合成的复合特定全营养配方。
本发明配方的主要成分为:
短肽:
本发明所述的短肽,即为低聚肽,是指利用生物酶工程技术从动物或植物蛋白中分离提取的一类小分子蛋白质。其平均分子量在1000Dalton以下,易溶于水,对酸、热稳定,可以不需经过消化而直接吸收,生物利用率高,在吸收和利用上优于游离的氨基酸和完整的蛋白质,可应用于蛋白质补充食品中。尤其对于消化和吸收能力减弱的人群,短肽是极佳的氮源。
除营养功能外,短肽还具有一系列的生理活性功能:
1.提高小肠的消化吸收功能。短肽可以改善小肠粘膜组织形态结构,增加小肠绒毛的高度和表面积,加深隐窝的深度,改善和维持肠壁粘膜细胞结构和功能的完整性。
2.增强机体免疫力。短肽可以增加巨噬细胞的吞噬率和吞噬指数,增强淋巴细胞的增殖能力,促进抗体形成细胞数量增加,提高机体的免疫水平。
3.抗氧化。短肽可以增加谷胱甘肽过氧化物酶(GSH-Px)、超氧化物歧化酶(SOD)、过氧化氢酶(CAT)的活性,降低脂质过氧化物丙二醛(MAD)的水平,从而发挥抗氧化功能。
4.辅助调节血糖。动物实验表明,短肽具有降低糖尿病大鼠空腹血糖水平的趋势,但对正常大鼠的空腹血糖水平无明显影响。
5.辅助调节血脂。短肽可以降低血清总胆固醇和低密度脂蛋白胆固醇的水平。
6.辅助降血压。
7.抗辐射。短肽有助于维持机体皮肤细胞结构和功能的完整性,减轻辐射损伤。
8.促进矿物质吸收。短肽在肠道内通过与矿物质如钙、铁、锌等的螯合,提高矿物质的转运比例,增加矿物质的吸收率。
9.增强药食两用中草药中功能因子的作用效果。短肽与中草药中的功能因子如活性多糖等具有协同作用,能够提高其增强机体免疫力、抗疲劳的效果。
本发明所述的短肽是指海洋鱼低聚肽、大豆蛋白肽、乳清蛋白肽、卵白蛋白肽、海参肽、牡蛎肽、豌豆蛋白肽、小麦低聚肽、玉米低聚肽其中一种、几种或全部混合。
本发明所述的海洋鱼低聚肽是指以深海鱼(如三文鱼、鳕鱼等)的鱼皮或鱼骨为原料,利用生物酶解技术,提取的小分子蛋白质,其平均分子量低于1000Dalton。
本发明所述的大豆蛋白肽是指以大豆蛋白质为原料,利用生物酶解技术,提取的小分子蛋白质,其平均分子量低于1000Dalton。
本发明所述的乳清蛋白肽是指以牛乳的乳清蛋白为原料,利用生物酶解技术,提取的小分子蛋白质,其平均分子量低于1000Dalton。
本发明所述的卵白蛋白肽是指以卵蛋白(如鸡蛋蛋白)为原料,利用生物酶解技术,提取的小分子蛋白质,其平均分子量低于1000Dalton。
本发明所述的海参肽是指以海参为原料,利用生物酶解技术,提取的小分子蛋白质,其平均分子量低于1000Dalton。
本发明所述的牡蛎肽是指以牡蛎为原料,利用生物酶解技术,提取的小分子蛋白质,其平均分子量低于1000Dalton。
本发明所述的豌豆蛋白肽是指以豌豆蛋白质为原料,利用生物酶解技术,提取的小分子蛋白质,其平均分子量低于1000Dalton。
本发明所述的小麦低聚肽肽是指以小麦蛋白质为原料,利用生物酶解技术,提取的小分子蛋白质,其平均分子量低于1000Dalton。
本发明所述的玉米低聚肽是指以玉米蛋白质为原料,利用生物酶解技术,提取的小分子蛋白质,其平均分子量低于1000Dalton。
药食两用中草药浓缩提取物:
薏苡仁浓缩提取物
薏苡仁具有水渗透湿,健脾止泻,除痹,排脓,解毒散结的作用,同时有助于清热排脓和治肌肉风湿。现代医学已证实,薏仁油作用于蛙肌,确能使肌肉挛缩减少,这就为前人的经验“薏苡仁治湿痹拘挛”提供了初步的科学根据。薏苡仁油低浓度,对蛙的骨骼肌和运动神经末梢有兴奋作用, 高浓度则呈麻痹作用.亦能减少在体及离体蛙肌肉的挛缩,并缩短其疲劳曲线。薏苡素对横纹肌有抑制作用.能抑制蛙神经肌肉标本的电刺激所引起的收缩反应及大鼠膈肌的氧摄取和无氧糖酵解, 并能抑制肌动球蛋白-三磷酸腺苷系统的反应.
酸枣仁浓缩提取物
酸枣仁具有养心补肝,宁心安神,敛汗,生津的功效,主治虚烦不眠,惊悸多梦,体虚多汗,津伤口渴。酸枣仁在安神、失眠领域有其独到的见解,且疗效显著,被医生患者美称“东方睡果”。医典籍《神农本草经》中很早就有记载,酸枣可以“安五脏,轻身延年”。所以,千万不要小看这种野果,它具有很大的药用价值,可以起到养肝、宁心、安神、敛汗的作用。医学上常用它来治疗神经衰弱、心烦失眠、多梦、盗汗、易惊等病。同时,又能达到一定的滋补强壮效果。
桑葚浓缩提取物
桑椹性味甘寒,具有补肝益肾、生津润燥、乌发明目等功效。现代研究证实,桑葚果实中含有丰富的活性蛋白、维生素、氨基酸、胡萝卜素、矿物质、白藜芦醇、花青素等成份,营养是苹果的5~6倍,是葡萄的4倍,具有多种功效,被医学界誉为“21世纪的最佳保健果品”。桑椹中含有脂肪酸,主要由亚油酸。硬脂酸及油酸组成,具有分解脂肪,降低血脂,防止血管硬化等作用;桑椹中含有鞣酸、脂肪酸、苹果酸等营养物质,能帮助脂肪、蛋白质及淀粉的消化,故有健脾胃助消化之功,可用于治疗因消化不良而导致的腹泻;桑椹中所含的芸香苷、花色素、葡萄糖、果糖、苹果酸、钙质、无机盐、胡萝卜素、多种维生素及烟酸等成分,都有预防肿瘤细胞扩散,提高免疫力,避免癌症发生的功效。
杏仁浓缩提取物
杏仁富含蛋白质、脂肪、糖类、胡萝卜素、B族维生素、维生素C、维生素P以及钙、磷、铁等营养成分。其中胡萝卜素的含量在果品中仅次于芒果,人们将杏仁称为抗癌之果。杏仁含有丰富的脂肪油,有降低胆固醇的作用,因此,杏仁对防治心血管系统疾病有良好的作用;中医中药理论认为,杏仁具有生津止渴、润肺定喘的功效,常用于肺燥喘咳等患者的保健与治疗。美国研究人员的一项最新研究成果显示,胆固醇水平正常或稍高的人,可以用杏仁取代其膳食中的低营养密度食品,达到降低血液胆固醇并保持心脏健康的目的。研究者认为,杏仁中所富含的多种营养素,比如维生素E,单不饱和脂肪和膳食纤维共同作用能够有效降低心脏病的发病危险。
白扁豆浓缩提取物
白扁豆“健脾胃,清暑湿。用于脾胃虚弱、暑湿泄泻、白带”。
白扁豆具有抗菌,抗病毒作用,可增强免疫功能能,有一定抗肿瘤活性。故其既是滋补上品,又是一味良药,有补脾胃,和中化湿,消暑解毒的作用,用于脾胃虚弱,食欲不佳,大便溏泻,白带过多,暑湿吐泻,胸闷肚胀等症。白扁豆中包含淀粉酶抑制物在身体内有降血糖的功效;白扁豆中的植物血细胞凝集素能令癌细胞发生凝集反应,肿瘤细胞表面发生结构变化,进而发挥细胞解毒的功效,并且能够促进淋巴细胞的转化,增强对肿瘤的免疫能力,抑制肿瘤的生长,起到防癌抗癌的作用;白扁豆包含对病毒的抑制成份,这类活性成份在水溶性的高分子与低分子部分都有,这类成份能有效地抑制病毒的生长;白扁豆包含多类微元素,刺激骨髓造血组织,减少粒细胞的破坏,提高造血功能,对白细胞减少症有效。
甘草浓缩提取物
甘草含有多种化学成分,主要成分有甘草酸、甘草甙等。用于脾胃虚弱,倦怠乏力,心悸气短,咳嗽痰多,脘腹、四肢挛急疼痛,痈肿疮毒,缓解药物毒性、烈性等症。甘草有类似肾上腺皮质激素样作用,对组胺引起的胃酸分泌过多有抑制作用;并有抗酸和缓解胃肠平滑肌痉挛作用;甘草中所含的甘草黄酮、甘草浸膏及甘草次酸均有明显的镇咳作用,祛痰作用也较显著;甘草还有抗炎,抗过敏作用,能保护发炎的咽喉和气管粘膜。甘草浸膏和甘草酸对某些毒物有类似葡萄糖醛酸的解毒作用;甘草所含的次酸能阻断致癌物诱发肿瘤生长的作用。
本发明所述的药食两用中草药浓缩提取物为薏苡仁浓缩提取物、酸枣仁浓缩提取物、桑葚浓缩提取物、杏仁浓缩提取物、白扁豆浓缩提取物、甘草浓缩提取物其中的一种、数种或全部混合。
本发明所述的薏苡仁浓缩提取物是指薏苡仁干粉水提浓缩,将浓缩液喷雾干燥而制备的粉状物质。
本发明所述的酸枣仁浓缩提取物是指将酸枣仁干粉水提浓缩,将浓缩液喷雾干燥而制备的粉状物质。
本发明所述的桑葚浓缩提取物是指将桑葚干粉水提浓缩,将浓缩液喷雾干燥而制备的粉状物质。
本发明所述的杏仁浓缩提取物是指将杏仁干粉水提浓缩,将浓缩液喷雾干燥而制备的粉状物质。
本发明所述的白扁豆浓缩提取物是指将白扁豆干粉水提浓缩,将浓缩液喷雾干燥而制备的粉状物质。
本发明所述的甘草浓缩提取物是指将甘草干粉水提浓缩,将浓缩液喷雾干燥而制备的粉状物质。
肌酸:
肌酸是由精氨酸、甘氨酸及甲硫氨酸三种氨基酸所合成的物质。可以由人体自行合成,也可以由食物中摄取。肌酸是人体内自然产生的一种氨基酸衍生物,它可以快速增加肌肉力量,加速疲劳恢复,提高爆发力。肌酸在人体内储存越多,力量及运动能力也越强。及时补充肌酸可以有效的提高肌力、速度和耐力,防止疲劳。
β-羟基-β-甲基丁酸钙(HMB):
β-羟基-β-甲基丁酸钙(HMB)是亮氨酸的代谢产物,对肌肉的质量和力量上有明显的改善作用,可有效促进肌肉再生,提高肌力量与LBM;可增加蛋白合成,防止肌肉流失;同时抑制肌肉蛋白降解,保护肌肉组织。研究显示,补充足够的HMB,可以防止患者因长期卧床或者年龄增长引起的肌肉衰减,维持瘦体重和肌肉量,有助于改善营养不良老年患者的营养状况,降低死亡率;能显著改善老年人的生活质量和握力,促进老年骨折患者术后的伤口愈合,减少住院时间。
低聚糖:
低聚糖又称寡糖,是指由2~10个单糖通过糖苷键连接形成的直链或支链的低度聚合糖。功能性低聚糖不被人体消化吸收,也不被大多数的肠道腐败菌利用,但可以促进人体内有益细菌——双歧杆菌的生长繁殖,从而可以抑制腐败菌生长,有助于改善和维持肠道正常功能。长期食用可以延缓衰老、通便、提高免疫力、减轻肝脏负担、提高营养吸收率,特别是能够改善机体对钙、铁、锌离子的吸收。
本发明所述的低聚糖为低聚半乳糖、低聚异麦芽糖、低聚果糖、大豆低聚糖、低聚木糖其中的一种、几种或全部混合。
欧米伽-6脂肪酸(亚油酸):
亚油酸是人和动物营养中必需的脂肪酸。亚油酸人体不能合成,或是合成的量远不能满足需要的脂肪酸,叫做必需脂肪酸。亚油酸是公认的一种必需脂肪酸。由于亚油酸能降低血液胆固醇,预防动脉粥样硬化而倍受重视。研究发现,胆固醇必须与亚油酸结合后,才能在体内进行正常的运转和代谢。如果缺乏亚油酸,胆固醇就会与一些饱和脂肪酸结合,发生代谢障碍,在血管壁上沉积下来,逐步形成动脉粥样硬化,引发心脑血管疾病。
欧咪伽-3脂肪酸(α-亚麻酸):
α—亚麻酸作为生长、细胞代谢及肌肉运动供能只是其功能的一部分,其更多是作为结构物质和代谢调控物质,发挥结构功能和调控功能。在α—亚麻酸降低血清胆固醇的机理中,除增加胆固醇排泄外,抑制内源性胆固醇合成也很重要。HMG-CoA是胆固醇合成的主要限速酶,α-亚麻酸抑制其活性而减少胆固醇的合成。Tield等发现,摄入α—亚麻酸能使家兔肝HMG-CoA还原酶活性降低,同时使ACAT活性升高。α—亚麻酸对脂肪合成酶系的抑制和加强线粒体中的β-氧化,使甘油三酯的合成减少而消耗增加。
维生素和矿物质:
维生素和矿物质是人体必需的营养素。本发明中添加的维生素为维生素A、维生素D、维生素E、维生素K、维生素C、维生素B1、维生素B2、维生素B6、维生素B12、烟酸、叶酸、泛酸、胆碱、生物素其中的一种、几种或全部混合。
本发明中添加的矿物质为钙、磷、钾、钠、镁、氯、铁、锌、硒、铜、锰、碘、钼其中的一种、几种或全部混合。本发明所述的矿物质添加为该矿物质的有机或无机化合物。
本发明中维生素矿物质的添加量参照《食品安全国家标准 特殊医学用途配方食品通则》(GB 29922)和《食品安全国家标准 食品营养强化剂使用标准》(GB 14880)执行。
上述各种配料混合均匀,可保持其粉状,或经过造粒,制成粉状或颗粒状食品。
本发明的技术优点:
本发明将现代营养学研究成果与传统养生保健理论相结合,研制了一种采用食源性活性短肽、药食两用中草药浓缩提取物、肌酸、新资源食品β-羟基-β-甲基丁酸钙(HMB)、低聚糖、亚油酸、α-亚麻酸、维生素和矿物质等混合配制的特殊医学配方食品。通过各种配料的有机组合,将各种功能进行融合,并通过有效成分之间的协同作用,增强作用效果。按本发明配方制作的食品不仅可以及时补充肌肉衰减综合征人群需要的优质蛋白质、维生素,不增加肝肾负担;亦可增加其蛋白合成,防止肌肉流失;可以防止患者因长期卧床或者年龄增长引起的肌肉衰减,维持瘦体重和肌肉量,有助于改善营养不良老年患者的营养状况,降低死亡率,从而进一步有效防治慢病的发展。本配方食品的特性及其对机体的作用主要表现在以下几个方面:
1)食品具有等渗性
利用本发明配方,各种组分采用适宜的比例搭配制备的食品,经一定量的水溶解后呈等渗状态,能快速通过胃到达小肠,吸收快,无残渣,不增加胃肠及肝脏负担。所含氮源来自短肽,易于吸收利于,不增加肾脏负担。
2)发挥更好的营养效果
本发明配方食品以多种来源的短肽为氮源,因为短肽不需消化即可吸收,多种短肽形成平衡的氨基酸模式,更有利于机体的利用。可以在一定程度上改善自然分娩待产产妇的负氮平衡。
本发明配方食品含多种维生素和矿物质,可迅速补充肌肉衰减综合征人所需营养。短肽通过与钙、铁、锌等的螯合后,更增加了矿物质元素的吸收率。
3)抑制肌肉蛋白降解,保护肌肉组织;促进肌肉再生,提高肌力
本发明配方食品的β-羟基-β-甲基丁酸钙(HMB)、肌酸具有促进肌肉再生,提高肌力量与LBM,增加蛋白合成,防止肌肉流失的诸多功效;
4)增强机体抵抗能力,增强肌力、提高免疫力
本发明配方食品的薏苡仁浓缩提取物、酸枣仁浓缩提取物、桑葚浓缩提取物、杏仁浓缩提取物、白扁豆浓缩提取物、甘草浓缩提取物等生理活性物质具有增强抵抗力、安神、增强肌力、提高免疫力的作用;短肽可以及时补充氮源,低聚糖通过促进肠道益生菌的生长繁殖也可以增强机体免疫力,短肽与活性多糖类物质具有协同作用。多个方面的因素联合,可以明显增强机体的抵抗能力、增强肌力、消除疲劳。
5)改善胃肠道功能
短肽能够改善肠粘膜上皮细胞的结构和功能,提高肠粘膜的吸收能力。低聚糖通过促进肠内益生菌的生长繁殖,抑制腐败菌的生长,同时在肠粘膜表面形成一道保护屏障,可以抵御肠道腐败菌对肠粘膜的损伤,减少肠内有害物质的吸收。低聚糖可以促进肠道蠕动,加速肠内残留物质的排出,有利于防止便秘。
6)增强机体的抗氧化、抗辐射能力等。
7)本发明配方中采用各种药食两用中草药的浓缩提取物,提高了功能因子的浓度,减少各种杂质的摄入,有助于减轻肝肾负担。
具体实施方式:
以下通过实施例对本发明作进一步说明。
实施例1 制备供肌肉衰减综合征人群食用的短肽特殊医学用途配方食品“力复康”短肽复合营养素(固体饮料)
本实施例选择粉状的乳清蛋白肽、大豆蛋白肽、β-羟基-β-甲基丁酸钙(HMB)、肌酸、脱脂乳粉、麦芽糊精、椰子粉、β-环状糊精、薏苡仁缩提取物、桑葚浓缩提取物、酸枣仁浓缩提取物、甘草浓缩提取物、低聚异麦芽糖、赤藓糖醇、甜菊糖苷、食用香精、亚油酸、α-亚麻酸及各种维生素和矿物质,按下列原料及其用量进行配方:
乳清蛋白肽6g、大豆蛋白肽4.5g、β-羟基-β-甲基丁酸钙(HMB)1g、肌酸0.7g、脱脂乳粉0.5g、麦芽糊精0.5g、椰子粉0.2g、β-环状糊精0.2g、薏苡仁缩提取物0.1g、桑葚浓缩提取物0.1g、酸枣仁浓缩提取物0.1g、甘草浓缩提取物0.1g、低聚异麦芽糖0.15g、赤藓糖醇0.035g、甜菊糖苷0.035g、麦香香精0.035
亚油酸0.3g、α-亚麻酸5mg
维生素A 140μg、维生素D 2.5μg、维生素C 30mg、维生素E 4μg、维生素B1 1.05mg、维生素B2 0.5mg、维生素B6 0.5mg、维生素B12 1μg、烟酸4.5mg、叶酸100μg
钙250mg、铁4mg、锌3mg
将上述原料混合,搅拌均匀,经过干燥,制成粉状食品。用约150ml温开水溶解后,直接饮用。
实施例2 制备供肌肉衰减综合征人群食用的短肽特殊医学用途配方食品“力复康”短肽复合营养素(固体饮料)
本实施例选择粉状的乳清蛋白肽、大豆蛋白肽、β-羟基-β-甲基丁酸钙(HMB)、肌酸、脱脂乳粉、麦芽糊精、椰子粉、β-环状糊精、薏苡仁缩提取物、桑葚浓缩提取物、酸枣仁浓缩提取物、甘草浓缩提取物、低聚异麦芽糖、赤藓糖醇、甜菊糖苷、食用香精及各种维生素和矿物质,按下列原料及其用量进行配方:
乳清蛋白肽2g、大豆蛋白肽1.5g、β-羟基-β-甲基丁酸钙(HMB)1g、肌酸0.7g、脱脂乳粉0.5g、麦芽糊精0.5g、椰子粉0.2g、β-环状糊精0.2g、薏苡仁缩提取物0.1g、桑葚浓缩提取物0.1g、酸枣仁浓缩提取物0.1g、甘草浓缩提取物0.1g、低聚异麦芽糖0.15g、赤藓糖醇0.035g、甜菊糖苷0.035g、麦香香精0.035
亚油酸0.3g、α-亚麻酸5mg
维生素A 140μg、维生素D 2.5μg、维生素C 30mg、维生素E 4μg、维生素B1 1.05mg、维生素B2 0.5mg、维生素B6 0.5mg、维生素B12 1μg、烟酸4.5mg、叶酸100μg
钙250mg、铁4mg、锌3mg
将上述原料混合,搅拌均匀,经过造粒、干燥,整粒,制成颗粒状。用约150ml温开水溶解后,直接饮用。
Claims (8)
1.一种供肌肉衰减综合征人群食用含短肽的全营养食品配方,其特征是以食源性生物活性短肽为主要原料,再添加传统的药食两用中草药浓缩提取物、β-羟基-β-甲基丁酸钙(HMB) 、肌酸、亚油酸、α-亚麻酸、低聚糖、维生素和矿物质,组成复合配方。
2.根据权利要求1所述的供肌肉衰减综合征人群食用含短肽的全营养食品配方,其特征是所述的短肽为海洋鱼低聚肽、大豆蛋白肽、乳清蛋白肽、海参肽、牡蛎肽、豌豆蛋白肽、小麦低聚肽、玉米低聚肽其中的一种、几种或者全部混合。
3.根据权利要求1所述的供肌肉衰减综合征人群食用含短肽的全营养食品配方,其特征是所述的药食两用中草药浓缩提取物为薏苡仁浓缩提取物、酸枣仁浓缩提取物、桑葚浓缩提取物、杏仁浓缩提取物、白扁豆浓缩提取物、甘草浓缩提取物其中的一种、几种或全部混合。
4.根据权利要求1所述的供肌肉衰减综合征人群食用含短肽的全营养食品配方,其特征是所述的β-羟基-β-甲基丁酸钙(HMB) 、肌酸、亚油酸、α-亚麻酸其中的一种、几种或全部混合。
5.根据权利要求1所述的供肌肉衰减综合征人群食用含短肽的全营养食品配方,其特征是所述的低聚糖为低聚异麦芽糖、低聚果糖、低聚木糖、低聚半乳糖其中的一种、几种或全部混合。
6.根据权利要求1所述的供肌肉衰减综合征人群食用含短肽的全营养食品配方,其特征是所述的维生素为维生素A、维生素D、维生素E、维生素C、维生素B1、维生素B2、维生素B2、维生素B12、烟酸、叶酸其中的一种、几种或全部混合。
7.根据权利要求1所述的供肌肉衰减综合征人群食用含短肽的全营养食品配方,其特征在于:所述的矿物质为钙、磷、钾、钠、镁、氯、铁、锌、硒、铜、锰、碘其中的一种、几种或全部混合。
8.根据权利要求1所述的供肌肉衰减综合征人群食用含短肽的全营养食品配方,其特征在于按照所述配方混合制备成粉状或颗粒状或液体状食品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711309348.9A CN107927797A (zh) | 2017-12-11 | 2017-12-11 | 一种供肌肉衰减综合征人群食用含短肽的全营养食品配方 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711309348.9A CN107927797A (zh) | 2017-12-11 | 2017-12-11 | 一种供肌肉衰减综合征人群食用含短肽的全营养食品配方 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107927797A true CN107927797A (zh) | 2018-04-20 |
Family
ID=61946500
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711309348.9A Pending CN107927797A (zh) | 2017-12-11 | 2017-12-11 | 一种供肌肉衰减综合征人群食用含短肽的全营养食品配方 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107927797A (zh) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108685100A (zh) * | 2018-04-27 | 2018-10-23 | 浙江禾健生营养食品有限公司 | 一种复合短肽粉配方及其制备方法 |
CN109077302A (zh) * | 2018-07-18 | 2018-12-25 | 辰欣药业股份有限公司 | 一种治疗和预防老年肌肉衰减综合症的医用食品及其制备方法 |
CN109090454A (zh) * | 2018-08-07 | 2018-12-28 | 广西弘山堂生物科技有限公司 | 一种猴菇养胃粉及其制备方法 |
CN109645496A (zh) * | 2018-12-07 | 2019-04-19 | 北京康比特体育科技股份有限公司 | 一种提高肌肉速度的组合物及其制备方法和应用 |
CN110934295A (zh) * | 2019-12-22 | 2020-03-31 | 重庆申高生化制药股份有限公司 | 具有强身养肾功效的组合物及制备方法 |
KR102087432B1 (ko) * | 2018-12-28 | 2020-04-20 | 한국해양과학기술원 | 홍해삼 효소 가수분해물을 유효성분으로 포함하는 근육질환 치료 또는 근력개선용 약학적 조성물 및 식품 조성물 |
CN111194925A (zh) * | 2018-11-19 | 2020-05-26 | 临沂山松药业有限公司 | 一种含大豆肽的全营养特殊医学用途配方食品及其制备方法 |
CN112006278A (zh) * | 2020-09-09 | 2020-12-01 | 宣城柏维力生物工程有限公司 | 速度力量型运动营养食品及其制备工艺 |
CN112868794A (zh) * | 2021-02-09 | 2021-06-01 | 赣州市全标生物科技有限公司 | 一种富含低致敏性异源免疫活性肽的老年型辅食营养包与其制备方法 |
CN113367349A (zh) * | 2020-02-25 | 2021-09-10 | 内蒙古蒙牛乳业(集团)股份有限公司 | 用于肌肉衰减综合征的组合物、其制备方法和用途 |
CN113662185A (zh) * | 2021-09-01 | 2021-11-19 | 北京西宏润美医药科技有限公司 | 包含hmb钙和乳清蛋白的肌肉衰减症人群专用营养乳剂 |
CN114403454A (zh) * | 2022-01-05 | 2022-04-29 | 陕西恒晟远誉生物医药科技有限公司 | 一种复合蛋白多肽钙粉 |
CN114680339A (zh) * | 2022-04-12 | 2022-07-01 | 天津医科大学 | 一种改善肌肉衰减延缓衰老的营养补充剂及其应用 |
CN115177000A (zh) * | 2021-04-07 | 2022-10-14 | 陕西罗麻丹医药有限公司 | 一种改善老年肌少症的粉剂及其制备方法 |
CN116804048A (zh) * | 2023-02-24 | 2023-09-26 | 中国农业大学 | 豌豆白蛋白分离肽、组合物及其用途 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006034586A1 (en) * | 2004-09-29 | 2006-04-06 | Aplodan Formulations Ltd. | Nutritional composition for promoting muscle performance and acting as hydrogen (h+) blocker |
CN101524155A (zh) * | 2009-04-20 | 2009-09-09 | 北京康比特体育科技股份有限公司 | 一种氨基酸组合物 |
CN101530195A (zh) * | 2008-01-28 | 2009-09-16 | 中国食品发酵工业研究院 | 一种供产妇食用含短肽的特殊膳食用食品配方 |
CN101530196A (zh) * | 2008-01-28 | 2009-09-16 | 中国食品发酵工业研究院 | 一种供术后患者食用含短肽的特殊膳食用食品配方 |
CN103783532A (zh) * | 2012-10-29 | 2014-05-14 | 杭州纽曲星生物科技有限公司 | 一种抗老年性肌肉衰减的复合蛋白质粉及其制备方法 |
WO2015048348A2 (en) * | 2013-09-25 | 2015-04-02 | Pronutria, Inc. | Compositions and formulations for increasing renal function and treatment and prevention of renal diseases, and methods of production and use thereof |
CN104855975A (zh) * | 2015-04-22 | 2015-08-26 | 劲膳美生物科技股份有限公司 | 肌肉衰减综合征非全营养配方食品 |
CN106072573A (zh) * | 2016-07-05 | 2016-11-09 | 郑州和正生物科技有限公司 | 一种适用于老年肌肉衰减症食用的特膳食品 |
CN107440107A (zh) * | 2017-09-18 | 2017-12-08 | 重庆市生物技术研究所有限责任公司 | 一种供妊娠反应人群食用含短肽的特殊膳食用食品配方 |
-
2017
- 2017-12-11 CN CN201711309348.9A patent/CN107927797A/zh active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006034586A1 (en) * | 2004-09-29 | 2006-04-06 | Aplodan Formulations Ltd. | Nutritional composition for promoting muscle performance and acting as hydrogen (h+) blocker |
CN101530195A (zh) * | 2008-01-28 | 2009-09-16 | 中国食品发酵工业研究院 | 一种供产妇食用含短肽的特殊膳食用食品配方 |
CN101530196A (zh) * | 2008-01-28 | 2009-09-16 | 中国食品发酵工业研究院 | 一种供术后患者食用含短肽的特殊膳食用食品配方 |
CN101524155A (zh) * | 2009-04-20 | 2009-09-09 | 北京康比特体育科技股份有限公司 | 一种氨基酸组合物 |
CN103783532A (zh) * | 2012-10-29 | 2014-05-14 | 杭州纽曲星生物科技有限公司 | 一种抗老年性肌肉衰减的复合蛋白质粉及其制备方法 |
WO2015048348A2 (en) * | 2013-09-25 | 2015-04-02 | Pronutria, Inc. | Compositions and formulations for increasing renal function and treatment and prevention of renal diseases, and methods of production and use thereof |
CN104855975A (zh) * | 2015-04-22 | 2015-08-26 | 劲膳美生物科技股份有限公司 | 肌肉衰减综合征非全营养配方食品 |
CN106072573A (zh) * | 2016-07-05 | 2016-11-09 | 郑州和正生物科技有限公司 | 一种适用于老年肌肉衰减症食用的特膳食品 |
CN107440107A (zh) * | 2017-09-18 | 2017-12-08 | 重庆市生物技术研究所有限责任公司 | 一种供妊娠反应人群食用含短肽的特殊膳食用食品配方 |
Non-Patent Citations (1)
Title |
---|
EWA JO´WKO等: "Creatine and b-Hydroxy-b-Methylbutyrate (HMB) Additively Increase Lean Body Mass and Muscle Strength During a Weight- Program", 《NUTRITION》 * |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108685100A (zh) * | 2018-04-27 | 2018-10-23 | 浙江禾健生营养食品有限公司 | 一种复合短肽粉配方及其制备方法 |
CN109077302A (zh) * | 2018-07-18 | 2018-12-25 | 辰欣药业股份有限公司 | 一种治疗和预防老年肌肉衰减综合症的医用食品及其制备方法 |
CN109090454A (zh) * | 2018-08-07 | 2018-12-28 | 广西弘山堂生物科技有限公司 | 一种猴菇养胃粉及其制备方法 |
CN111194925A (zh) * | 2018-11-19 | 2020-05-26 | 临沂山松药业有限公司 | 一种含大豆肽的全营养特殊医学用途配方食品及其制备方法 |
CN109645496A (zh) * | 2018-12-07 | 2019-04-19 | 北京康比特体育科技股份有限公司 | 一种提高肌肉速度的组合物及其制备方法和应用 |
CN109645496B (zh) * | 2018-12-07 | 2021-09-28 | 北京康比特体育科技股份有限公司 | 一种提高肌肉速度的组合物及其制备方法和应用 |
KR102087432B1 (ko) * | 2018-12-28 | 2020-04-20 | 한국해양과학기술원 | 홍해삼 효소 가수분해물을 유효성분으로 포함하는 근육질환 치료 또는 근력개선용 약학적 조성물 및 식품 조성물 |
CN110934295A (zh) * | 2019-12-22 | 2020-03-31 | 重庆申高生化制药股份有限公司 | 具有强身养肾功效的组合物及制备方法 |
CN113367349B (zh) * | 2020-02-25 | 2024-03-12 | 内蒙古蒙牛乳业(集团)股份有限公司 | 用于肌肉衰减综合征的组合物、其制备方法和用途 |
CN113367349A (zh) * | 2020-02-25 | 2021-09-10 | 内蒙古蒙牛乳业(集团)股份有限公司 | 用于肌肉衰减综合征的组合物、其制备方法和用途 |
CN112006278A (zh) * | 2020-09-09 | 2020-12-01 | 宣城柏维力生物工程有限公司 | 速度力量型运动营养食品及其制备工艺 |
CN112868794A (zh) * | 2021-02-09 | 2021-06-01 | 赣州市全标生物科技有限公司 | 一种富含低致敏性异源免疫活性肽的老年型辅食营养包与其制备方法 |
CN115177000A (zh) * | 2021-04-07 | 2022-10-14 | 陕西罗麻丹医药有限公司 | 一种改善老年肌少症的粉剂及其制备方法 |
CN113662185A (zh) * | 2021-09-01 | 2021-11-19 | 北京西宏润美医药科技有限公司 | 包含hmb钙和乳清蛋白的肌肉衰减症人群专用营养乳剂 |
CN114403454A (zh) * | 2022-01-05 | 2022-04-29 | 陕西恒晟远誉生物医药科技有限公司 | 一种复合蛋白多肽钙粉 |
CN114680339A (zh) * | 2022-04-12 | 2022-07-01 | 天津医科大学 | 一种改善肌肉衰减延缓衰老的营养补充剂及其应用 |
CN116804048A (zh) * | 2023-02-24 | 2023-09-26 | 中国农业大学 | 豌豆白蛋白分离肽、组合物及其用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107927797A (zh) | 一种供肌肉衰减综合征人群食用含短肽的全营养食品配方 | |
CN101496579B (zh) | 一种供肿瘤患者食用含短肽的特殊膳食用食品配方 | |
CN101496580B (zh) | 一种供糖尿病患者食用含短肽的特殊膳食用食品配方 | |
CN101530196B (zh) | 一种供术后患者食用含短肽的特殊膳食用食品配方 | |
CN101496577B (zh) | 一种供肾病患者食用含短肽的特殊膳食用食品配方 | |
CN101530195B (zh) | 一种供产妇食用含短肽的特殊膳食用食品配方 | |
CN108095072A (zh) | 供长期卧床及肌肉衰减综合征人群食用短肽特膳食品配方 | |
CN101496578B (zh) | 一种供肝病患者食用含短肽的特殊膳食用食品配方 | |
CN101496576B (zh) | 一种供骨伤患者食用含短肽的特殊膳食用食品配方 | |
CN102077939B (zh) | 一种肥胖人士专用的海洋特膳食品 | |
CN107440107A (zh) | 一种供妊娠反应人群食用含短肽的特殊膳食用食品配方 | |
CN108719984B (zh) | 一种针对痛风人群的代餐营养棒及其制备方法 | |
CN102077940A (zh) | 一种冠心病患者专用的海洋特膳食品 | |
CN107581599A (zh) | 一种供产妇自然分娩时食用含短肽的特殊膳食用食品配方 | |
CN104855994A (zh) | 肾病非全营养配方食品 | |
CN106107463A (zh) | 超级藜麦抗疲劳奶茶制作工艺 | |
CN104738624A (zh) | 一种神经衰弱、健忘失眠的营养保健食品 | |
CN102077944A (zh) | 一种前列腺患者专用的海洋特膳食品 | |
CN104856000A (zh) | 失眠非全营养配方食品 | |
CN105410930A (zh) | 一种具有减肥瘦身、均衡营养功能的保健品及其制备方法 | |
CN107410816A (zh) | 一种扶阳补元药食两用植物特膳食品 | |
CN110326776A (zh) | 一种适合航天员的提高免疫力的药食同源复合制剂 | |
CN104855960A (zh) | 创伤感染手术及其它应急状态非全营养配方食品 | |
CN103431396A (zh) | 一种解酒的天然植物含片及其制备工艺 | |
CN108208813A (zh) | 一种具有保健作用的减肥消脂片及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180420 |
|
WD01 | Invention patent application deemed withdrawn after publication |